131 related articles for article (PubMed ID: 11137708)
41. Role of calcium-calmodulin-dependent protein kinase II in modulation of sensorimotor synapses in Aplysia.
Nakanishi K; Zhang F; Baxter DA; Eskin A; Byrne JH
J Neurophysiol; 1997 Jul; 78(1):409-16. PubMed ID: 9242289
[TBL] [Abstract][Full Text] [Related]
42. Differential effects of omega-conotoxin GVIA, nimodipine, calmidazolium and KN-62 injected intrathecally on the antinociception induced by beta-endorphin, morphine and [D-Ala2,N-MePhe4,Gly-ol5]-enkephalin administered intracerebroventricularly in the mouse.
Suh HW; Song DK; Choi SR; Huh SO; Kim YH
J Pharmacol Exp Ther; 1997 Aug; 282(2):961-6. PubMed ID: 9262364
[TBL] [Abstract][Full Text] [Related]
43. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
44. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
45. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
Das CM; Aguilera D; Vasquez H; Prasad P; Zhang M; Wolff JE; Gopalakrishnan V
J Neurooncol; 2007 Nov; 85(2):159-70. PubMed ID: 17534580
[TBL] [Abstract][Full Text] [Related]
46. Potentiation of etoposide-induced cytotoxicity and DNA damage in CCRF-CEM cells by pretreatment with non-cytotoxic concentrations of arabinosyl cytosine.
Chresta CM; Hicks R; Hartley JA; Souhami RL
Cancer Chemother Pharmacol; 1992; 31(2):139-45. PubMed ID: 1333370
[TBL] [Abstract][Full Text] [Related]
47. Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells.
Fabian I; Reuveni D; Levitov A; Halperin D; Priel E; Shalit I
Br J Cancer; 2006 Oct; 95(8):1038-46. PubMed ID: 17047652
[TBL] [Abstract][Full Text] [Related]
48. Effect of KN-62, a selective inhibitor of calmodulin-dependent kinase II, on mouse oocyte activation.
Inagaki N; Suzuki S; Kitai H; Nakatogawa N; Kuji N; Iwahashi K; Yoshimura Y
J Assist Reprod Genet; 1997 Nov; 14(10):609-16. PubMed ID: 9447464
[TBL] [Abstract][Full Text] [Related]
49. Gene expression profiles in the fetal mouse brain after etoposide (VP-16) administration.
Nam C; Yamauchi H; He XJ; Woo GH; Ahn B; Nam SY; Doi K; Nakayama H
Exp Anim; 2013; 62(2):93-9. PubMed ID: 23615303
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of voltage-gated Ca2+ channels and insulin secretion in HIT cells by the Ca2+/calmodulin-dependent protein kinase II inhibitor KN-62: comparison with antagonists of calmodulin and L-type Ca2+ channels.
Li G; Hidaka H; Wollheim CB
Mol Pharmacol; 1992 Sep; 42(3):489-8. PubMed ID: 1328847
[TBL] [Abstract][Full Text] [Related]
51. Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors.
Bertrand R; Solary E; Jenkins J; Pommier Y
Exp Cell Res; 1993 Aug; 207(2):388-97. PubMed ID: 7688316
[TBL] [Abstract][Full Text] [Related]
52. KN-62, a specific Ca++/calmodulin-dependent protein kinase inhibitor, reversibly depresses the rate of beating of cultured fetal mouse cardiac myocytes.
Okazaki K; Ishikawa T; Inui M; Tada M; Goshima K; Okamoto T; Hidaka H
J Pharmacol Exp Ther; 1994 Sep; 270(3):1319-24. PubMed ID: 7932185
[TBL] [Abstract][Full Text] [Related]
53. The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex.
Gantchev TG; Hunting DJ
Mol Pharmacol; 1998 Mar; 53(3):422-8. PubMed ID: 9495807
[TBL] [Abstract][Full Text] [Related]
54. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
55. Cellular response to etoposide treatment.
Montecucco A; Biamonti G
Cancer Lett; 2007 Jul; 252(1):9-18. PubMed ID: 17166655
[TBL] [Abstract][Full Text] [Related]
56. Calcium/calmodulin-dependent protein kinase II involvement in release of gonadotropin-releasing hormone.
Waters WW; Chen PL; McArthur NH; Moreno PA; Harms PG
Neuroendocrinology; 1998 Mar; 67(3):145-52. PubMed ID: 9630431
[TBL] [Abstract][Full Text] [Related]
57. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
[TBL] [Abstract][Full Text] [Related]
58. Cytotoxicity and cell cycle effects of novel indolo[2,3-b]quinoline derivatives.
Humeniuk R; Kaczmarek L; Peczyńska-Czoch W; Marcinkowska E
Oncol Res; 2003; 13(5):269-77. PubMed ID: 12688678
[TBL] [Abstract][Full Text] [Related]
59. Etoposide-induced DNA damage in human tumor cells: requirement for cellular activating factors.
Sinha BK; Eliot HM
Biochim Biophys Acta; 1991 Sep; 1097(2):111-6. PubMed ID: 1655044
[TBL] [Abstract][Full Text] [Related]
60. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
